Mirati Therapeutics

Mirati Therapeutics is an American targeted oncology company that focuses on the development of cancer therapeutics.[1]

Mirati Therapeutics, Inc.
TypePublic company
IndustryOncology
Founded1995 (1995)
HeadquartersSan Diego, California, U.S.
Key people
David Meek
Number of employees
600 (2022)
Websitemirati.com

History

Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it.[2] The inhibition to the mutation has shown to shrink the size of its tumors.[3] The company is based in San Diego, California.[4] The company’s name comes from the Italian word for “targeted” (Mirati). Mirati Therapeutics is traded on the NASDAQ[5] under the ticker symbol MRTX.[6] It joined the exchange in 2013.[7]

Drug candidates

The company’s leading drug candidates are sitravatinib and adagrasib.[4] Mirati also has a preclinical candidate against the G12D mutation.[8]

Management

The company’s CEO and President is David Meek.[9]


References
  1. Flanagan C (25 October 2020). "Hedge Fund Pick Mirati Rallies to Record After Drug Results". BloombergQuint.
  2. Ingham E (1 January 2021). "Mirati Therapeutics: Paying $220 A Share Sounds Excessive But Cracking KRAS Is A Big Deal (NASDAQ:MRTX)". Seeking Alpha.
  3. Garage JL (October 28, 2019). "Mirati drug shrinks tumors in some cancer patients in early-stage trial". CNBC.
  4. Tran H (31 December 2020). "Mirati Therapeutics: A Gift That Keeps On Giving (NASDAQ:MRTX)". Seeking Alpha.
  5. Speights K (26 October 2020). "Why Mirati Therapeutics Stock Is Taking Off Today". The Motley Fool.
  6. BNK Invest (29 March 2021). "RSI Alert: Mirati Therapeutics (MRTX) Now Oversold". NASDAQ.
  7. Whitlock J (7 July 2021). "Mirati Therapeutics Raises $234.3M in Public Stock Offering". San Diego Business Journal.
  8. Martz L (26 October 2019). "How a KRAS program transformed Mirati's story". BioCentury.
  9. Mirati (20 September 2021). "Mirati Therapeutics Appoints David Meek as Chief Executive Officer".
  • Official website
  • Business data for Mirati Therapeutics:
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.